In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
To investigate the specificity of in vivo amyloid imaging with [(11)C]-Pittsburgh Compound B (PIB) in Parkinson disease dementia (PDD). We performed detailed neuropathologic examination for 3 individuals with PDD who had PIB PET imaging within 15 months of death. We observed elevated cortical uptake of [(11)C]-PIB on in vivo PET imaging in 2 of the 3 cases. At autopsy, all 3 individuals had abundant cortical Lewy bodies (Braak PD stage 6), and were classified as low-probability Alzheimer disease (AD) based on NIA-Reagan criteria. The 2 PIB-positive individuals had abundant diffuse Abeta plaques but only sparse neuritic plaques and intermediate neurofibrillary tangle pathology. The PIB-negative individual had rare diffuse plaques, no neuritic plaques, and low neurofibrillary tangle burden. [(11)C]-Pittsburgh Compound B (PIB) PET is specific for fibrillar Abeta molecular pathology but not for pathologic diagnosis of comorbid Alzheimer disease in individuals with Parkinson disease dementia. The ability to specifically identify fibrillar Abeta amyloid in the setting of alpha-synucleinopathy makes [(11)C]-PIB PET a valuable tool for prospectively evaluating how the presence of Abeta amyloid influences the clinical course of dementia in patients with Lewy body disorders.
In vivo amyloid imaging in autopsy-
confirmed Parkinson disease with dementia
M.A. Burack, MD, PhD
J. Hartlein, MSN
H.P. Flores, MS
L. Taylor-Reinwald, BA
J.S. Perlmutter, MD
N.J. Cairns, PhD
Objective: To investigate the specificity of in vivo amyloid imaging with [
pound B (PIB) in Parkinson disease dementia (PDD).
Methods: We performed detailed neuropathologic examination for 3 individuals with PDD who had
PIB PET imaging within 15 months of death.
Results: We observed elevated cortical uptake of [
C]-PIB on in vivo PET imaging in 2 of the 3
cases. At autopsy, all 3 individuals had abundant cortical Lewy bodies (Braak PD stage 6), and
were classified as low-probability Alzheimer disease (AD) based on NIA-Reagan criteria. The 2
PIB-positive individuals had abundant diffuse A
plaques but only sparse neuritic plaques and
intermediate neurofibrillary tangle pathology. The PIB-negative individual had rare diffuse
plaques, no neuritic plaques, and low neurofibrillary tangle burden.
C]–Pittsburgh Compound B (PIB) PET is specific for fibrillar A
but not for pathologic diagnosis of comorbid Alzheimer disease in individuals with Parkinson disease
dementia. The ability to specifically identify fibrillar A
amyloid in the setting of
C]-PIB PE T a valuable tool for prospectively evaluating how the presence of A
ences the clinical course of dementia in patients with Lewy body disorders.
AD ⫽ Alzheimer disease; BP ⫽ binding potentials; CDR ⫽ Clinical Dementia Rating; DAT ⫽ dementia of the Alzheimer type;
DLB ⫽ dementia with Lewy bodies; DV ⫽ distribution volume; MMSE ⫽ Mental State Examination; NPI-Q ⫽ Neuropsychiatric
Inventory Questionnaire; PDD ⫽ Parkinson disease dementia; PIB ⫽ Pittsburgh Compound B; UPDRS ⫽ Unified Parkinson’s
Disease Rating Scale.
Individuals with Parkinson disease (PD) are nearly 6 times more likely to develop dementia
than age-matched controls, and the majority of individuals with PD who survive more than 15
years after diagnosis will develop dementia.
Clinicopathologic investigations have revealed
heterogeneous histopathology, with Alzheimer disease (AD) pathology (amyloid plaques and
neurofibrillary tangles) present in a subset of individuals with PD dementia (PDD).
present, AD pathology is typically found in conjunction with other neuropathologic changes,
including limbic and cortical Lewy bodies and degeneration of subcortical monoaminergic and
cholinergic pathways. The contribution of AD pathology to the pathogenesis of dementia in
the setting of PD is thus uncertain. The presence of AD pathology has been postulated to
influence clinical manifestations of dementia, for example masking features of dementia with
Lewy bodies (DLB) such as hallucinations and fluctuations
or influencing the timing of
dementia onset in patients with Lewy body disorders.
Antemortem evaluation of A
plaque burden by PET imaging using amyloid-specific radiotrac-
ers can potentially clarify the role of these lesions in the pathogenesis of Lewy body–associated
dementias (PDD and DLB). The tracer N-methyl-[
hydroxybenzothiazole (or [
C]-PIB for Pittsburgh Compound-B) has shown great promise for
this purpose, demonstrating rapid diffusion across the blood– brain barrier, high affinity to a
From the Departments of Neurology (M.A.B.) and Pediatrics (M.A.B.), University of Rochester School of Medicine and Dentistry, Rochester, NY;
and Alzheimer’s Disease Research Center (L.T.-R., N.J.C.), Department of Neurology (M.A.B., J.H., H.P.F., L.T.-R., J.S.P., N.J.C.), Department of
Pathology & Immunology (N.J.C.), Program in Physical Therapy (J.S.P.), Department of Radiology (J.S.P.), Program in Occupational Therapy
(J.S.P.), and Department of Anatomy & Neurobiology (J.S.P.), Washington University School of Medicine, St. Louis, MO.
Disclosure: Author disclosures are provided at the end of the article.
Supplemental data at
Address correspondence and
reprint requests to Dr. Michelle
A. Burack, Department of
Neurology and Pediatrics, 601
Elmwood Avenue, Box 673,
University of Rochester Medical
Center, Rochester, NY 14642
Copyright © 2010 by AAN Enterprises, Inc. 77
single binding site on synthetic A
(Kd ⫽ 4.7
nM), and high affinity to a single binding site
in homogenates of frontal cortex from brains
with AD (Kd ⫽ 1.4 nM).
PET images of
C]-PIB in individuals with dementia of the
Alzheimer type (DAT) reveal widespread in-
creased tracer uptake in neocortical regions,
with relative sparing of the occipital and sen-
sory/motor cortices and minimal uptake in
the cerebellar cortex.
In an ongoing cohort study, we have per-
C]-PIB PET imaging in individuals
with Lewy body disorders (including cognitively
normal PD, PDD, and DLB) followed by longi-
tudinal clinical and psychometric assessments.
All enrolled participants have consented to post-
mortem neuropathologic evaluation. Our pre-
liminary results, reported previously in abstract
form, are consistent with findings of other
with a subset of individuals
with Lewy body disorders (⬃20%) demonstrat-
ing elevated cortical [
port here the postmortem neuropathologic
findings for 3 individuals with PDD who had in
C]-PIB PET imaging and subsequently
METHODS Standard protocol approvals, registra-
tions, and patient consents.
All study procedures were ap-
proved by Washington University’s Human Research Protection
Office. Prior to enrollment, written informed consent was ob-
tained for all participants. For individuals lacking capacity due to
dementia, a surrogate decision-maker (spouse, first-degree family
member, or health care proxy) provided informed consent and
ongoing assent was obtained from the participant throughout
the study procedures.
Subject selection and clinical assessment. Individuals
were recruited from the greater St. Louis area; there were no
gender or race restrictions. Participants with clinically probable
or definite idiopathic PD (modified United Kingdom PD Brain
were screened via detailed clinical his-
tory (including review of motor, cognitive, and neuropsychiatric
symptoms, comorbid medical conditions, and medications) and
neurologic examination. Exclusionary criteria included other
conditions that could contribute substantially to the subject’s
motor and/or cognitive impairment, including neurologic (e.g.,
Parkinson-plus disorders other than DLB), psychiatric (e.g., ma-
jor affective disorders, unless cognitive impairment and mood
symptoms were clearly temporally dissociated), or medical con-
ditions (e.g., drug-induced or other delirium). From October
2006 to March 2009, we enrolled 10 healthy elderly control
individuals and 40 individuals with iPD or DLB. Three of the
enrolled participants subsequently died and donated their brains
for the study.
All 3 of the deceased participants met clinical diagnostic cri-
teria for PDD
; none had a known family history of dementia or
PD. Individual histories are provided in appendix e-1 on the
Web site at www.neurology.org, and clinical data are
summarized in table 1. Motor symptoms were assessed using the
Unified Parkinson’s Disease Rating Scale (UPDRS) subscale 3
(motor subscale) and Hoehn-Yahr staging while having benefit
from medication (ON state). Levodopa equivalent daily dose
was calculated using the following corrections: dose levodopa in
sustained release form ⫻ 0.75; dose of levodopa taken with
catechol-O-methyltransferase inhibitor ⫻ 1.3. None of the 3
participants reported here took a dopamine agonist or mono-
amine oxidase inhibitor at the time of the evaluation.
Severity of dementia was staged according to the Clinical
Dementia Rating (CDR).
Impairment of function in 6 do-
mains (memory, orientation, judgment and problem solving,
community affairs, home and hobby, and personal care) is rated
on a 0–3 scale (0 ⫽ normal; 1 ⫽ mild; 2 ⫽ moderate; 3 ⫽
severe). Global (weighted average) and sum CDR ratings are
presented. Other standardized assessments included Mini-
Mental State Examination (MMSE
), Neuropsychiatric Inven-
tory Questionnaire (NPI-Q
), and Mayo Fluctuations scale.
In vivo amyloid imaging. [
C]-PIB was synthesized accord-
ing to published methods.
PET imaging was performed using a
Siemens 961 HR ECAT PET scanner (CTI, Knoxville, TN).
Approximately 12 mCi of radiotracer (range, 10.4 –14.5; specific
activity ⱖ1,200 Ci/mmol) was injected via an antecubital vein,
and a 60-minute, 3-dimensional (septa retracted) dynamic PET
scan was collected. Images were reconstructed as 5-minute
frames using scatter correction and a ramp filter. Frames were
corrected for head motion using in-house software, and coregis-
Table 1 Clinical data
(ON) H-Y stage LEDD, mg MMSE
NPI-Q Mayo fluct.Global
1(M) 18 4 40 4 1,260 23 2 12 20 2
2(F) 17 10 35 4 600 11 2 14 24 4
3(M) 19 5 35 2 1,115 24 1 7 20 4
UPDRS3 ⫽ Unified Parkinson’s Disease Rating Scale (motor subscale, maximum 108) during ON medication state; H-Y ⫽
Hoehn and Yahr stage; LEDD ⫽ levodopa equivalent daily dose; MMSE ⫽ Mini-Mental State Examination score (maximum
score 30); CDR Global ⫽ Clinical Dementia Rating global score (0 ⫽ cognitively normal; 0.5 ⫽ very mild dementia; 1 ⫽ mild
dementia; 2 ⫽ moderate dementia; 3 ⫽ severe dementia); CDR Sum ⫽ sum of individual ratings for 6 domains of cognitive
function (maximum score 18); NPI-Q ⫽ Neuropsychiatric inventory questionnaire (maximum score 39); Mayo Fluct. ⫽ Mayo
fluctuations score (maximum score 4).
78 Neurology 74 January 5, 2010
tered to the patient’s T1-weighted magnetization-prepared rapid
gradient echo magnetic resonance scan obtained the same day.
For visual display, the data from 30 to 60 minutes after radio-
tracer injection were summed, Gaussian filtered (full width half-
maximum ⫽ 6 mm), and normalized to average brainstem
For quantitative analyses, 3-dimensional regions of interest
(prefrontal cortex, gyrus rectus, lateral temporal cortex, precu-
neus, occipital lobe, caudate nucleus, brainstem, and cerebellum)
were created for each subject based on their individual MRI
scans, with boundaries defined as previously described.
activity curves were analyzed using Logan graphical analysis,
with the cerebellum (which has minimal specific binding due to
plaque content) as the reference tissue input function.
Binding potentials (BP) were calculated from the tracer distribu-
tion volume (DV, reflected in the slope of the Logan graphical
analysis) as BP ⫽ DV ⫺ 1. Mean cortical binding potentials
were calculated for each subject as the average of all cortical
regions except occipital lobe (which typically has lower A
plaque burden, even in advanced AD). For comparison, pub-
lished mean values of MCBP calculated using identical methods
are 0.63 in DAT and 0.09 in age-matched controls
greater than 0.2 are associated with low CSF A
are considered abnormally elevated.
Neuropathology. Brains were fixed in 10% neutral buffered
formalin for 2 weeks, paraffin wax-embedded, and sections cut at
m. Blocks were taken from frontal, temporal, parietal, and
occipital lobes, thalamus, striatum including the nucleus basalis
of Meynert, amygdala, hippocampus, midbrain, pons, medulla
oblongata, and the cervical spinal cord. Histologic stains in-
cluded hematoxylin and eosin and modified Bielschowsky silver
impregnation. Immunohistochemistry was performed using the
following antibodies: A
(10D5, Elan Pharmaceuticals, San
Francisco, CA), phosphorylated tau (PHF-1, supplied by Dr.
Peter Davies, Albert Einstein Medical School, Bronx, NY), ubiq-
uitin (Dako, Glostrup, Denmark),
Zymed, CA), and TDP-43 (Proteintech, Inc., Chicago, IL).
Amyloid and tau burden was scored semiquantitatively in each
of the sampled regions (0 ⫽ none; 1 ⫽ few/mild; 2 ⫽ moderate;
3 ⫽ severe);
-synucleinopathy with Lewy bodies was rated ac-
cording to the scheme proposed by McKeith et al.
where 0 ⫽
none; 1 ⫽⬍1 Lewy body per ⫻ 10 microscopic field; 2 ⫽ 1–3
Lewy bodies; 3 ⫽ 4 –10 Lewy bodies; and 4 ⫽⬎10 or numerous
In vivo amyloid imaging. Images repre-
senting the distribution of [
C]-PIB PET activity
from 30 to 60 minutes after tracer injection are
shown in figure 1. Images from a 77-year-old female
control participant without neurologic disease are
displayed for comparison. Visual inspection revealed
high signal in multiple cortical areas for 2 patients
(case 1 and case 2), with relative sparing of primary
sensorimotor and visual cortex. This pattern was
highly similar to that previously described for pa-
tients clinically diagnosed with DAT.
trast, case 3 and the control participant showed
uptake predominantly in white matter regions. This
likely reflects nonspecific retention, as a recent study
showed that PIB binding to white matter homoge-
nates is nonsaturable.
Binding potentials for selected regions of interest
and mean cortical binding potentials for the 3 indi-
viduals are presented in table 2. Cases 1 and 2 had
elevated PIB binding potentials in multiple cortical
regions, with relative sparing of the occipital cortex.
Case 1 also had elevated binding in the caudate nu-
cleus. In contrast, case 3 had binding potentials near
zero for all regions.
Neuropathology. Macroscopic findings included
mild frontal, temporal, and parietal atrophy and dila-
tation of the lateral ventricles (less in case 3 than in
cases 1 and 2), and normal hippocampal size in all 3
cases. As expected, there was pronounced loss of pig-
ment in the substantia nigra (see representative im-
ages in figure e-1 on the Neurology
Web site at
Histologic findings for case 2 are illustrated in
figure 2. In the substantia nigra, there was neuronal
loss, extracellular pigment, gliosis, Lewy bodies, and
Lewy neurites (figure 2, B and C). The parahip-
pocampal gyrus contained abundant Lewy bodies
(figure 2D) and moderate neurofibrillary tangle pa-
thology (figure 2G). Extensive A
deposits in the
frontal lobe were evident by immunohistochemistry
(figure 2A); there was also cerebral amyloid angiopa-
thy in leptomeningeal vessels.
Regional semiquantitative assessments of A
-synuclein burden for the 3 cases are presented
in table 3. All 3 cases had abundant Lewy bodies in
multiple neocortical and limbic regions. Cases 1 and
2 also had a high burden of A
(Braak amyloid stage C
), predominantly in the
form of diffuse plaques. Although a few isocortical
neurofibrillary tangles were seen in these 2 cases, they
were very sparse and thus overall neurofibrillary tan-
gle burden was rated as limbic stage (Braak NFT
). In contrast, case 3 had minimal A
plaques (Braak amyloid stage A), and only sparse
transentorhinal and entorhinal neurofibrillary tan-
gles (Braak NFT stage I). Cerebral amyloid angiopa-
thy was mild in case 1 and absent in the other 2 cases.
Modest vascular pathology in the form of arteriolo-
sclerosis was also a feature of all 3 brains (not shown).
There were no infarcts in any of the 3 cases.
The presence of Lewy bodies in brainstem, lim-
bic, and neocortical areas was consistent with PD
stage 6 (range: 0 – 6) in all 3 cases.
The density and
distribution of these lesions was also sufficient to
meet “high probability” criteria for dementia with
; because the parkinsonism preceded
the cognitive changes by more than 1 year, the entity
which describes these clinicopathologic features is
called PDD rather than DLB.
In cases 1 and 2, the
numerous neocortical A
plaques were sufficient for
neuropathologic diagnosis of AD by Khachaturian
Neurology 74 January 5, 2010 79
but the modest numbers of neuritic
plaques and neocortical tangles were only sufficient
to fulfill the criteria for “possible” AD according to
Consortium to Establish a Registry for Alzheimer’s
and there was only a “low likeli-
hood” that the cognitive changes are caused by AD
according to the NIA-Reagan Institute criteria.
other neurodegenerative diseases were identified in
any of the three cases.
DISCUSSION The absence of elevated cortical
C]-PIB binding in an individual with PDD who
had abundant cortical Lewy bodies and minimal cor-
tical amyloid plaque pathology underscores the spec-
ificity of this tracer for fibrillar A
amyloid in in vivo
imaging. Previous in vitro studies have demonstrated
that PIB does not demonstrate specific binding to
Lewy bodies (an amyloid composed of fibrillar
) in cortex homogenates from patients
with Lewy body dementia lacking A
plaque, or to
evaluation of individuals who underwent amyloid
imaging strongly supports the notion that PIB PET
is specific for A
amyloid plaque pathology in vivo in
patients with Lewy body disorders. The burden of
cortical Lewy bodies in case 3 was comparable to that
Figure 1 [
C]-PIB PET images
(A) Case 1. (B) Case 2. Increased signal is evident in multiple cortical areas in these 2 individuals, including orbitofrontal and
prefrontal cortex, precuneus, and temporal lobes. (C) Case 3. (D) Control participant. These 2 individuals have minimal PIB
signal in cortical areas. PIB retention in white matter areas is likely due to nonspecific binding (see text).
Table 2 Regional and mean cortical binding
potentials (unitless ratio)
Case 1 Case 2 Case 3
Prefrontal cortex (A) 0.49 0.33 ⫺0.08
Temporal cortex (B) 0.40 0.35 ⫺0.02
Precuneus 0.68 0.41 0.00
Gyrus rectus 0.45 0.47 ⫺0.11
Occipital cortex (C) 0.12 0.19 0.04
Caudate nucleus (D) 0.47 0.04 ⫺0.21
Mean cortical binding
0.50 0.39 ⫺0.05
Letters in parentheses are provided for cross-referencing
to the corresponding regions sampled for histopathologic
evaluation (see table 3).
80 Neurology 74 January 5, 2010
in the other 2 cases, yet cortical retention of PIB was
not elevated in this individual. Only the 2 cases with
high levels of cortical A
detected by immunohisto-
chemistry had elevated cortical retention of PIB on
in vivo imaging. Our methodology did not permit
detailed quantitative correlations between regional
PIB uptake and A
lesion burden on histopathology,
as previously reported for a case of AD.
less, all measured cortical regions with an elevated
PIB binding potential (⬎0.2) in our study had severe
(grade 3) A
An unexpected finding in our study was that the 2
PIB-positive PDD cases had low probability AD by
NIA-Reagan criteria. Evolving criteria for neuro-
pathologic diagnosis of AD account for some of the
conflicting results regarding the role of AD pathol-
ogy in the pathogenesis of PDD.
Establish a Registry for Alzheimer’s Disease and
NIA-Reagan criteria emphasize neuritic rather than
plaques as the major correlate of dementia
in AD. However, diffuse plaques may be the pre-
dominant pathology in the earliest, mild stages of
AD, and may indicate preclinical AD in cognitively
The PIB-positive individuals
in this study had more advanced dementia (CDR
stage 2), a stage at which neuritic plaques are nearly
universally present in patients with DAT.
the setting of PD, [
C]-PIB PET may have insuffi-
cient specificity for antemortem diagnosis of comor-
bid AD due to the inability to distinguish between
diffuse and neuritic A
Since Lewy body pathology was advanced in all
cases, regardless of A
was likely central to the pathogenesis of PDD in
these individuals. However, since A
pathologies may interact synergistically,
it is possible
that the presence of diffuse A
plaque influences the
evolution of dementia in individuals with PD, even
in the absence of neurofibrillary tangle pathology in-
dicative of comorbid AD. Diffuse A
typically abundant in cases with cortical Lewy bod-
and Lewy body counts are highly correlated
with amyloid plaque counts in PD and PDD.
However, the timing of deposition of amyloid, Lewy
bodies, and neurofibrillary tangles relative to clinical
manifestations of dementia can only be inferred from
postmortem studies. Serial imaging to measure the
rate of amyloid deposition
in individuals with and
without Lewy body disorders (subsequently con-
firmed by autopsy) can directly test whether
-synucleinopathy exacerbates amyloidosis and ac-
celerates cognitive decline.
longitudinal follow-up of PIB-positive and PIB-
negative individuals with PD will be valuable for
ascertaining whether comorbid A
Figure 2 Postmortem examination, microscopic (case 2)
(10D5) immunohistochemistry. Low-power micrograph shows extensive A
the frontal lobe; there is also cerebral amyloid angiopathy in some leptomeningeal vessels. (B)
Hematoxylin and eosin. In the substantia nigra, there is neuronal loss, extracellular pigment,
gliosis, and a Lewy body (arrow) in a surviving pigmented neuron. (C–F)
immunohistochemistry. (C) Lewy bodies and a Lewy neurite in the substantia nigra are more
readily seen by
-synuclein immunohistochemistry. (D) Lewy bodies are present in the parahip-
pocampal gyrus. (E) Lewy bodies are present in subfield CA4 of the hippocampus. (F) Dystro-
phic neurites are present in the CA1/CA2 subfields of the hippocampus. (G) Phosphorylated tau
(PHF-1) immunohistochemistry. Neurofibrillary tangles and neuropil threads are present in the
parahippocampal gyrus. (A, D–F bar ⫽ 500
m; B, C, G, bar ⫽ 100
Neurology 74 January 5, 2010 81
ences the timing of onset, rate of progression, or
spectrum of clinical manifestations in PDD. This in-
formation will be crucial for developing targeted
therapies that can slow or prevent the onset of de-
mentia in patients with PD.
The authors thank the clinical, radiology, pathology, and technical staff
for making information and tissue samples available for this study and the
families of patients for participation. The authors thank the members of
the Alzheimer Disease Research Center at Washington University for help
with training in Clinical Dementia Rating.
This study was funded by NIH grants P01-AG03991, P50-AG05681,
U01-AG16976, K01-HD048437, R01-S041509, 5 T32-N2007205,
UL1 RR024992 (Clinical Science Translational Award at Washington
University), P30NS05710 (Neuroscience Blueprint Grant at Washington
University), American Parkinson Disease Association (APDA) Center for
Advanced PD Research at Washington University; Greater St. Louis
Chapter of the APDA; and the Barnes-Jewish Hospital Foundation (the
Elliot H. Stein Family Fund and the Jack Buck Fund for PD Research).
Dr. Burack receives salary and research support from the American Acad-
emy of Neurology (Clinical Research Training Fellowship), Medtronic,
Inc. (training fellowship), and foundation grants through the University
of Rochester; and during the study enrollment period her spouse held
stock in Amgen, Medtronic, Inc., Novartis, Pfizer Inc., Wyeth, and Astra-
Zeneca. J. Hartlein and H.P. Flores report no disclosures. L. Taylor-
Reinwald receives research support as study coordinator/research assistant
from the NIH/NIA [P01-AG03991 and P50-AG05681]. Dr. Perlmutter
serves on scientific advisory boards for the American Parkinson Disease
Association and the Dystonia Medical Research Foundation; serves on the
editorial boards of Neurology
; has received honoraria from Ceregene, the
Parkinson Disease Study Group (grant reviews), the NIH (review activi-
ties), and for speaking and educational activities not sponsored by indus-
try; and has received/receives research support from Medtronic, Inc.
(partial fellowship support), the NIH [RO1 1RO1NS41509 (PI), RO1
NS050425 (PI), RO1 NS058714 (PI), P30 NS057105 (Co-I Core B),
NCRR RR024992 (Project PI), R01ES013743 (Co-I), R01 NS039821
(Co-I), R01NS058797 (Co-I), and CO6 RR020092 (Program Direc-
tor)], the Huntington Disease Society of America, HiQ Foundation,
Bander Medical Business Ethics Foundation at Washington University,
McDonnell Center for Higher Brain Function, the Michael J. Fox Foun-
dation, Greater St. Louis Chapter of the American Parkinson Disease
Association, American Parkinson Disease Association, APDA Advanced
PD Research Center at Washington University, and the Barnes-Jewish
Hospital Foundation. Dr. Cairns serves on the editorial boards of Acta
Neuropathologica and Brain Pathology and receives research support from
Table 3 Regional molecular pathology
Case 1 Case 2 Case 3
Tau Syn A
Tau Syn A
DP CP CAA NFT NP LB DP CP CAA NFT NP LB DP CP CAA NFT NP LB
Middle frontal gyrus (A) 321 1 03 310 1 02 100 0 02
321 0 03 310 1 03 100 0 03
Prefrontal gyrus 311 0 03 310 1 02 000 0 03
311 1 03 310 1 13 000 0 02
Inferior parietal lobule 321 0 02 310 0 03 100 0 02
Occipital lobe (C) 112 0 00 211 0 00 000 0 01
Amygdala 310 1 04 310 1 03 000 0 03
Entorhinal cortex 311 2 03 310 2 03 000 1 03
Hippocampal CA1 100 1 12 000 1 01 000 1 02
Parahippocampal gyrus 311 3 13 210 2 13 000 1 03
Striatum (D) 300 0 01 310 1 01 100 0 01
Nucleus basalis of
311 1 03 300 1 03 000 1 03
Globus pallidus 100 0 01 000 0 01 000 0 00
Thalamus 200 1 02 300 1 01 000 1 02
Substantia nigra 100 0 03 000 1 02 000 0 03
Locus coeruleus 100 1 01 100 0 03 000 0 03
Basis pontis 000 0 00 000 0 00 000 0 00
Medulla oblongata 000 0 03 000 1 03 000 0 03
Cerebellum 001 0 00 000 0 01 000 0 01
CAA ⫽ cerebral amyloid angiopathy; CP ⫽ cored plaque; DP ⫽ diffuse plaque; LB ⫽ Lewy body; NFT ⫽ neurofibrillary tangle;
NP ⫽ neuritic plaque; PIB ⫽ Pittsburgh Compound B; 0 ⫽ none; 1 ⫽ few/mild; 2 ⫽ moderate; 3 ⫽ severe; 4 (Lewy bodies
only) ⫽ numerous/very severe.
Letters in parentheses are provided for a subset of regions to facilitate cross-referencing to the corresponding PIB-PET
imaging data presented in table 2.
82 Neurology 74 January 5, 2010
the NIH [P01-AG03991 (Neuropathology Core PI) and P50-AG05681
(Neuropathology Core PI)], and the Charles and Joanne Knight Alzhei-
mer Research Initiative.
Received June 18, 2009. Accepted in final form October 12, 2009.
1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic
criteria for dementia associated with Parkinson’s disease.
Mov Disord 2007;22:1689–1707.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris
JG. The Sydney Multicenter Study of Parkinson’s Disease:
the inevitability of dementia at 20 years. Mov Disord
3. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzhei-
mer pathology on clinical diagnostic accuracy in dementia
with Lewy bodies. Neurology 2003;60:1586 –1590.
4. Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical
and pathologic features of two groups of patients with demen-
tia with Lewy bodies: effect of coexisting Alzheimer-type le-
sion load. Alzheimer Dis Assoc Disord 2001;15:31– 44.
5. Ballard C, Ziabreva I, Perry R, et al. Differences in neuro-
pathologic characteristics across the Lewy body dementia
spectrum. Neurology 2006;67:1931–1934.
6. Klunk WE, Wang Y, Huang GF, et al. The binding of
2-(4⬘-methylaminophenyl) benzothiazole to postmortem
brain homogenates is dominated by the amyloid compo-
nent. J Neurosci 2003;23:2086 –2092.
7. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional
multiphoton imaging of brain entry, amyloid binding, and
clearance of an amyloid-beta ligand in transgenic mice.
Proc Natl Acad Sci USA 2003;100:12462–12467.
8. Klunk WE, Engler H, Nordberg A, et al. Imaging brain
amyloid in Alzheimer’s disease with Pittsburgh
Compound-B. Ann Neurol 2004;55:306 –319.
9. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB bind-
ing in Parkinson’s disease dementia. Neuroimage 2008;39:
10. Gomperts SN, Rentz DM, Moran E, et al. Imaging amy-
loid deposition in Lewy body diseases. Neurology 2008;
11. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in
Parkinson’s disease dementia and Lewy body dementia
measured with [11C]PIB positron emission tomography.
J Neurol Neurosurg Psychiatry 2008;79:1331–1338.
12. Burack MA, Campbell MC, Foster ER, et al. Relationship
of cortical Pittsburgh compound B (PIB) binding and clin-
ical features in Parkinson disease dementia. Mov Disord
13. Racette BA, Rundle M, Parsian A, Perlmutter JS. Evalua-
tion of a screening questionnaire for genetic studies of Par-
kinson’s disease. Am J Med Genet 1999;88:539 –543.
14. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and
management of dementia with Lewy bodies: third re-
port of the DLB Consortium. Neurology 2005;65:
15. Morris JC. The Clinical Dementia Rating (CDR): current
version and scoring rules. Neurology 1993;43:2412–2414.
16. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”:
a practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res 1975;12:189 –198.
17. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of
the NPI-Q, a brief clinical form of the Neuropsychiatric
Inventory. J Neuropsychiatry Clin Neurosci 2000;12:
18. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations:
specific features that reliably differentiate DLB from AD
and normal aging. Neurology 2004;62:181–187.
19. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML,
Klunk WE. Synthesis and evaluation of 11C-labeled
6-substituted 2-arylbenzothiazoles as amyloid imaging
agents. J Med Chem 2003;46:2740 –2754.
20. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a
nondemented population: potential antecedent marker of
Alzheimer disease. Neurology 2006;67:446 –452.
21. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS,
Alexoff DL. Distribution volume ratios without blood
sampling from graphical analysis of PET data. J Cereb
Blood Flow Metab 1996;16:834 –840.
22. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation
between in vivo amyloid imaging load and cerebrospinal
fluid Abeta42 in humans. Ann Neurol 2006;59:512–519.
23. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-
mortem correlates of in vivo PiB-PET amyloid imaging in
a typical case of Alzheimer’s disease. Brain 2008;131:
24. Fodero-Tavoletti MT, Rowe CC, McLean CA, et al.
Characterization of PiB binding to white matter in Alz-
heimer disease and other dementias. J Nucl Med 2009;
25. Braak H, Braak E. Neuropathological stageing of
Alzheimer-related changes. Acta Neuropathol 1991;82:
26. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del
Tredici K. Staging of Alzheimer disease-associated neurofi-
brillary pathology using paraffin sections and immunocy-
tochemistry. Acta Neuropathol 2006;112:389 –404.
27. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen
Steur EN, Braak E. Staging of brain pathology related
to sporadic Parkinson’s disease. Neurobiol Aging 2003;
28. Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch
29. Mirra SS, Heyman A, McKeel D, et al. The Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD):
part II: standardization of the neuropathologic assessment
of Alzheimer’s disease. Neurology 1991;41:479 – 486.
30. The National Institute on Aging, and Reagan Institute
Working Group on Diagnostic Criteria for the Neuro-
pathological Assessment of Alzheimer’s Disease. Consen-
sus recommendations for the postmortem diagnosis of
Alzheimer’s disease. Neurobiol Aging 1997;18:S1–S2.
31. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ,
Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Na-
ture 1997;388:839 –840.
32. Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In
vitro characterization of Pittsburgh compound-B binding
to Lewy bodies. J Neurosci 2007;27:10365–10371.
33. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson
DW. Parkinson disease neuropathology: later-developing
dementia and loss of the levodopa response. Arch Neurol
34. Morris JC, Storandt M, McKeel DW Jr, et al. Cerebral
amyloid deposition and diffuse plaques in “normal” aging:
evidence for presymptomatic and very mild Alzheimer’s
disease. Neurology 1996;46:707–719.
Neurology 74 January 5, 2010 83
35. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic
studies in cognitively healthy aging and Alzheimer’s dis-
ease: relation of histologic markers to dementia severity,
age, sex, and apolipoprotein E genotype. Arch Neurol
36. Masliah E, Rockenstein E, Veinbergs I, et al. beta-amyloid
peptides enhance alpha-synuclein accumulation and neu-
ronal deficits in a transgenic mouse model linking Alzhei-
mer’s disease and Parkinson’s disease. Proc Natl Acad Sci
37. Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease
and Lewy body disease: a comparative clinicopathological
study. Ann Neurol 1994;35:81– 88.
38. Dickson DW, Crystal H, Mattiace LA, et al. Diffuse Lewy
body disease: light and electron microscopic immunocyto-
chemistry of senile plaques. Acta Neuropathol 1989;78:
39. Lashley T, Holton JL, Gray E, et al. Cortical alpha-
synuclein load is associated with amyloid-beta plaque bur-
den in a subset of Parkinson’s disease patients. Acta
Neuropathol 2008;115:417– 425.
40. Jack CR, Jr., Lowe VJ, Weigand SD, et al. Serial PIB
and MRI in normal, mild cognitive impairment and
Alzheimer’s disease: implications for sequence of patho-
logical events in Alzheimer’s disease. Brain 2009;132:
Start Planning Your Trip to the 62
Meeting in Canada Today!
What You Need to Know to Get You There
Now is the time to start planning your trip to Canada—and if you are a visitor, it is important that
you know about valid travel documentation requirements and proof of citizenship. Here are some
important things to keep in mind when planning your trip:
● Document requirements vary depending from which country you are traveling, the reason for
your visit, the length of your stay
● Special no-fee passports may be required for US federal government employees
● The US Department of State now offers expedited passport service for US residents
For additional information on traveling to Canada, including tips on customs and immigration,
currency, health insurance, luggage requirements, and mobile phone service, visit www.aan.com/
84 Neurology 74 January 5, 2010